Compare Novartis AG (NVS) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Target Corporation — how do they compare? Novartis AG trades at $139.46 (market cap $262.64B), while Target Corporation trades at $158 (market cap $73.92B). The key difference: Novartis AG is far larger — about 3.6× Target Corporation's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NVS | TGT | |
|---|---|---|
Market Cap | $262.64B | $73.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $169.90 |
52-Week Low | $121.80 | $83.68 |
Enterprise Value | $303.97B | $87.20B |
Dividend Yield | 3.44% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Target Corporation (TGT) trades at $162.71, down 1.05% on the day, with strong technical momentum and solid fundamentals. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue remains stable around $107 billion with improving profitability margins. Recent news highlights CEO Michael Fiddelke's successful turnaround strategy and the company's expanding non-merchandise revenue streams.
Target presents a balanced investment case with fair valuation metrics and strong dividend history, though competitive retail pressures and valuation expansion pose risks. Analyst consensus leans slightly bullish with a $166.67 price target, representing modest upside potential from current levels. The company's operational efficiency improvements and digital growth initiatives support continued earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
